Pharmaceutical Medicine

Scope & Guideline

Advancing the frontiers of pharmacological research.

Introduction

Welcome to your portal for understanding Pharmaceutical Medicine, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1178-2595
PublisherSPRINGER INT PUBL AG
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2000 to 2001, from 2008 to 2024
AbbreviationPHARM MED / Pharm. Med.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGEWERBESTRASSE 11, CHAM CH-6330, SWITZERLAND

Aims and Scopes

The journal 'Pharmaceutical Medicine' focuses on advancing knowledge and practices in the pharmaceutical industry, particularly in the areas of drug development, regulatory affairs, and medical affairs. Its core aims and scopes include:
  1. Pharmaceutical Research and Development:
    Exploration of methodologies and innovations in drug discovery, development, and approval processes, with a focus on enhancing efficiency and effectiveness.
  2. Regulatory Affairs and Compliance:
    Analysis of regulatory frameworks, compliance challenges, and evolving guidelines affecting drug approval and market access across various regions.
  3. Medical Affairs and Education:
    Investigation into the role of medical affairs in the pharmaceutical industry, including education strategies for healthcare providers and engagement with patients.
  4. Pharmacovigilance and Drug Safety:
    Emphasis on monitoring drug safety post-marketing, signal detection, and implementation of risk minimization measures to ensure patient safety.
  5. Patient-Centric Approaches:
    Incorporation of patient perspectives in drug development and clinical trials, focusing on adherence, preferences, and outcomes.
  6. Emerging Technologies in Pharmaceuticals:
    Assessment of the impact of digital technologies, artificial intelligence, and real-world evidence on pharmaceutical practices and healthcare delivery.
Recent publications in 'Pharmaceutical Medicine' have highlighted several emerging themes that reflect the current trends and priorities in the pharmaceutical landscape. These areas are gaining attention and are likely to shape future research directions. The following points outline these trending and emerging scopes:
  1. Artificial Intelligence and Machine Learning Applications:
    The increasing integration of AI and machine learning in drug development and pharmacovigilance indicates a significant trend towards leveraging technology to enhance efficiency and data analysis.
  2. Patient-Centric Drug Development:
    A growing emphasis on patient engagement and the incorporation of patient preferences in clinical trial design and drug development processes showcases a shift towards more patient-centered approaches.
  3. Real-World Evidence Utilization:
    The use of real-world data to inform decision-making in drug approval and post-marketing assessments is emerging as a critical area of focus, reflecting the industry's need for better understanding of drug effectiveness in diverse populations.
  4. Diversity, Equity, and Inclusion in Clinical Trials:
    Increasing attention to diversity and inclusion within clinical trial populations highlights the industry's commitment to addressing health disparities and ensuring equitable access to treatments.
  5. Decentralized Clinical Trials:
    The rise of decentralized clinical trials, facilitated by technology and remote monitoring, represents a significant shift in how clinical studies are conducted, aiming to improve patient participation and data collection.

Declining or Waning

While 'Pharmaceutical Medicine' has consistently focused on various critical aspects of pharmaceutical science, certain themes have shown a decline in prominence over recent years. These waning scopes may reflect shifting priorities within the field or the maturation of certain topics. The following points summarize these declining themes:
  1. Traditional Clinical Trial Models:
    There is a noticeable decrease in publications focusing on conventional clinical trial methodologies, possibly due to the rise of decentralized trials and adaptive designs.
  2. Single-Use Drug Formulations:
    Research on single-use formulations seems to be declining as the industry shifts towards more comprehensive therapeutic strategies and complex drug delivery systems.
  3. Pharmaceutical Marketing Strategies:
    Discussions around traditional pharmaceutical marketing tactics are less frequent, indicating a shift towards more integrated and value-based approaches to market access.
  4. Regulatory Challenges in Established Markets:
    The focus on regulatory challenges specific to established markets (e.g., EU, USA) is diminishing, possibly as the industry adapts to newer regulatory frameworks and harmonization efforts.
  5. Post-Marketing Studies:
    There appears to be a reduction in studies solely dedicated to post-marketing surveillance of drugs, as new methodologies for real-world evidence gain traction.

Similar Journals

Journal of Pharmacy and Bioallied Sciences

Bridging Theory and Practice in Bioengineering
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0976-4879Frequency: 6 issues/year

The Journal of Pharmacy and Bioallied Sciences is a premier open access publication that has been contributing to the fields of Pharmacy, Bioengineering, and Biochemistry since its establishment in India, under the esteemed Wolters Kluwer Medknow Publications. With the ISSN 0976-4879 and E-ISSN 0975-7406, this journal provides a platform for high-quality research articles, reviews, and clinical studies aimed at advancing knowledge and practice in the pharmaceutical and allied sciences. As a reflection of its academic stature, the journal holds a respectable categorization within the third and fourth quartiles in pertinent fields according to the latest metrics, with rankings that place it among prominent emerging research in pharmacology and biochemistry. Researchers and professionals are encouraged to access a wealth of knowledge freely, as the journal has been open access since 2010. The journal not only aims to foster innovative research but also strives to bridge the gap between pharmaceutical sciences and real-world applications, making it an essential resource for students, academics, and industry experts alike.

Clinical Pharmacology in Drug Development

Transforming clinical practices with groundbreaking research.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

International Journal of Pharmaceutical Investigation

Enhancing Global Health Through Rigorous Investigation
Publisher: INPHARM ASSOC, PHCOG NETISSN: 2230-973XFrequency: 4 issues/year

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

DARU-Journal of Pharmaceutical Sciences

Advancing pharmaceutical knowledge for a healthier tomorrow.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Pharmaceutical Sciences

Bridging research and practice to transform healthcare.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

Journal of Reports in Pharmaceutical Sciences

Unveiling the Future of Biopharmaceutical Technologies.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Advancing pharmaceutical knowledge, one article at a time.
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0031-6903Frequency: 12 issues/year

YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

Journal of Pharmaceutical Health Care and Sciences

Fostering collaboration for transformative healthcare solutions.
Publisher: BMCISSN: 2055-0294Frequency: 1 issue/year

The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.

Iranian Journal of Pharmaceutical Research

Advancing pharmaceutical knowledge for a healthier tomorrow.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Elevating standards in clinical pharmacy and patient care.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.